Brefeldin A

Drug Profile

Brefeldin A

Alternative Names: BFA; NSC 89671

Latest Information Update: 28 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Braton Biotech; Nonindustrial source
  • Class Cytostatic antibiotics; Macrolides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; HIV infections; Inflammation

Most Recent Events

  • 07 Sep 2000 No-Development-Reported for HIV infections treatment in USA (Unknown route)
  • 31 Aug 2000 A preclinical study has been added to the Cancer pharmacodynamics section
  • 19 May 1999 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top